Insulet Corporation (ISIN US45784P1012) opened at USD 140.53 on Nasdaq on September 22, 2026, near the lower end of its ...

At the close on September 18, 2026, Insulet stock finished at USD 140.60 on Nasdaq with a negligible percent move, holding ...

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products ...

Insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its Omnipod 5 insulin delivery Pods in the U.S. after detecting that some devices had a manufacturing defect that causes ...

Insulet Corporation entered into the Ninth Amendment to Credit Agreement with the lenders and other parties thereto and Morgan Stanley Senior Funding Inc., as administrative agent, amending that ...

McEvoy invested $162,217 at a weighted average price of $147.47, bringing total beneficial ownership to 23,735 shares valued at $3.52 million.

U.S. equities were little changed at midday with the market awaiting the key earnings report from Nvidia tomorrow.

Diabetes management is evolving rapidly as the industry innovates to treat the more than 40 million Americans with type 1 or type 2 diabetes. Deciding between two leaders in monitoring and treatment, ...

Insulet ( ) has provided an update. On September 14, 2026, Insulet ’s Talent and Compensation Committee approved a Nonqualified Deferred Compensation Plan, effective January 1, ...

Baron Capital, an investment management company, released its second-quarter 2026 investor letter for its “Baron SMID Cap ETF ...

Harvey Stober, senior equity analyst and correspondent at CNBC, explains why this medical device manufacturer's proximity to the weight loss space grows the company's total addressable market, and the ...